RRC ID 78780
Author Singaram I, Sharma A, Pant S, Lihan M, Park MJ, Pergande M, Buwaneka P, Hu Y, Mahmud N, Kim YM, Cologna S, Gevorgyan V, Khan I, Tajkhorshid E, Cho W.
Title Targeting lipid-protein interaction to treat Syk-mediated acute myeloid leukemia.
Journal Nat Chem Biol
Abstract Membrane lipids control the cellular activity of kinases containing the Src homology 2 (SH2) domain through direct lipid-SH2 domain interactions. Here we report development of new nonlipidic small molecule inhibitors of the lipid-SH2 domain interaction that block the cellular activity of their host proteins. As a pilot study, we evaluated the efficacy of lipid-SH2 domain interaction inhibitors for spleen tyrosine kinase (Syk), which is implicated in hematopoietic malignancies, including acute myeloid leukemia (AML). An optimized inhibitor (WC36) specifically and potently suppressed oncogenic activities of Syk in AML cell lines and patient-derived AML cells. Unlike ATP-competitive Syk inhibitors, WC36 was refractory to de novo and acquired drug resistance due to its ability to block not only the Syk kinase activity, but also its noncatalytic scaffolding function that is linked to drug resistance. Collectively, our study shows that targeting lipid-protein interaction is a powerful approach to developing new small molecule drugs.
Volume 19(2)
Pages 239-250
Published 2023-2-1
DOI 10.1038/s41589-022-01150-z
PII 10.1038/s41589-022-01150-z
PMID 36229686
PMC PMC9898191
MeSH Humans Intracellular Signaling Peptides and Proteins / metabolism Leukemia, Myeloid, Acute* / drug therapy Lipids Phosphorylation Pilot Projects Protein-Tyrosine Kinases* / metabolism Syk Kinase / metabolism src Homology Domains
Resource
Human and Animal Cells DT40(RCB1464) Syk^(-) DT40(RCB1470)